Agendia receives CE mark for MammaPrint BluePrint Breast Cancer Recurrence and Molecu
 

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.

More...